Can a common cholesterol drug boost immunotherapy against head and neck cancer?
NCT ID NCT06636734
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Researchers will measure how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lovastatin and pembrolizumab
What this could lead to
If it works, this could point toward a more effective treatment for recurrent or metastatic head and neck cancer by combining a common cholesterol drug with immunotherapy.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The combination may not work better than pembrolizumab alone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact